Demographic characteristic of patients in phase I
| Healthy controls (n=6) | UC patients (n=29) | |
| Female gender | 5 (83%) | 13 (45%) |
| Age at time of procedure (years): median (IQR) | 48.9 (36.3–60.9) | 43.6 (38.1–56.7) |
| Age at diagnosis (years): median (IQR) | NA | 32.6 (24.2–43.7) |
| Disease duration (months): median (IQR) | NA | 166 (85–219) |
| Smoking status | NA | Never 14/27 (52%) Stopped 12/27 (44%) Current 1//27 (4%) |
| Disease extension (Montreal) | NA | E1: 8/29 (27.6%) E2: 14/29 (48.3%) E3: 7/29 (24.1%) |
| Current treatment | NA | 5-ASA 23/29 (79%) Steroids 3/29 (10%) IMM 3/29 (10%) Anti-TNF 4/29 (14%) Vedolizumab 5/29 (17%) |
| Previous treatments | NA | 5-ASA 29/29 (100%) Steroids 25/29 (86%) IMM 14/29 (48%) Anti-TNF 12/29 (41%) Vedolizumab 4/29 (14%) |
5-ASA, 5-aminosalycic acid; E, extension; IMM, immunomodulator; NA, not applicable; TNF, tumour necrosis factor.